The first clinical experience of direct gene therapy using VEGF and bFGF in treatmentpatients with critical lower limb ischemia

M V Plotnikov; A A Rizvanov; R F Masgutov; M O Mavlikeev; I I Salafutdinov; I M Gazizov; Y D Romanova; I I Shamsutdinova; A A Bogov; A V Maksimov

doi:10.23868/gc121717

Genes & Cells ›› 2012, Vol. 7 ›› Issue (3) : 180 -184. DOI: 10.23868/gc121717

Articles

other

The first clinical experience of direct gene therapy using VEGF and bFGF in treatmentpatients with critical lower limb ischemia

Author information +

Republican Clinical Hospital, Kazan

Kazan State Medical Academy, Kazan

Republican Clinical Hospital, Kazan

Kazan (Volga Region) Federal University, Kazan

Kazan State Medical University, Kazan

Republican Clinical Hospital, Kazan;Kazan State Medical Academy, Kazan;

Republican Clinical Hospital, Kazan;Kazan (Volga Region) Federal University, Kazan;

Republican Clinical Hospital, Kazan;Kazan (Volga Region) Federal University, Kazan;Kazan State Medical University, Kazan;

Kazan State Medical University, Kazan

Republican Clinical Hospital, Kazan;Kazan (Volga Region) Federal University, Kazan;

Kazan State Medical University, Kazan

Kazan (Volga Region) Federal University, Kazan

Republican Clinical Hospital, Kazan

Republican Clinical Hospital, Kazan;Kazan State Medical University, Kazan;

Republican Clinical Hospital, Kazan;Kazan State Medical Academy, Kazan;

Show less

History +

PDF

Abstract

In this paper we present the clinical observation ofsuccessful treatment of distal form of peripheral arterydisease of the lower extremity with symptoms of criticalischemia in a 60 years old patient.Intramuscular injection of dual expression plasmid, encodingvascular endothelial growth factor VEGF and basic fibroblastgrowth factor FGF2, was performed to the affected lowerextremity. The effect of treatment was evaluated by functionaltests: measurement of ankle-brachial index, treadmill test, therecovery time, shoulder-ankle index after strain and temporaryocclusion. Performed immunohistochemical examination ofbiopsy samples of the affected lower extremity muscles.

Keywords

dual expression plasmid / peripheral artery disease / critical ischemia / gene therapy / muscle biopsies / dual expression plasmid / peripheral artery disease / critical ischemia / gene therapy / muscle biopsies

Cite this article

Download citation ▾

M V Plotnikov, A A Rizvanov, R F Masgutov, M O Mavlikeev, I I Salafutdinov, I M Gazizov, Y D Romanova, I I Shamsutdinova, A A Bogov, A V Maksimov. The first clinical experience of direct gene therapy using VEGF and bFGF in treatmentpatients with critical lower limb ischemia. Genes & Cells, 2012, 7(3): 180-184 DOI:10.23868/gc121717

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Савельев B.C., Кошкин В.М. Критическая ишемия нижних конечностей. М.: Медицина; 1997.

[2]	Criqui M.H., Fronek A., Barrett-Connor E. et al. The prevalence of peripheral arterial disease in a defined population. Circulation 1985; 71(3): 510-5.

[3]	Hiatt W.R., Hoag S., Hamman R.F. Effect of diagnostic criteria on the prevalence of peripheral arterial disease. The San Luis Valley Diabetes Study. Circulation 1995; 1; 91(5): 1472-9.

[4]	Selvin E., Erlinger T.P. Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999-2000. Circulation 2004; 110(6): 738-43.

[5]	Muluk S.C., Muluk V.S., Kelley M.E. et al. Outcome events in patients with claudication: A 15-year study in 2777 patients. J. Vasc. Surg. 2001; 33: 251-8.

[6]

Комаров А.Л, Панченко Е.Л., Деев А.Д. и др. Течение пере- межающейся хромоты и прогноз больных атеросклеротическим поражением артерий нижних конечностей. Анализ результатов про- спективного наблюдения. Ангиология и сосудистая хирургия 2000; 6(2): 9-18. 7. The Vascular Surgical Society of Great Britain and Ireland. Critical limb ischemia: management and outcome. Report of a national servey. Eur. J. Vas. Endovasc. Surg. 1995; 10: 108-13.

[7]

Hirsch A.T., Haskal Z.J., Hertzer N.R. et al. ACC/AHA 2005 Guidelines for the Management of Patients with Peripheral Arterial Disease (Lower Extremity, Renal, Mesenteric, and Abdominal Aortic):A Collaborative Report from the American Association for VascularSurgery/Society for Vascular Surgery, Society for CardiovascularAngiography and Interventions, Society for Vascular Medicine andBiology, Society of Interventional Radiology, and the ACC/AHA TaskForce on Practice Guidelines (Writing Committee to Develop Guidelinesfor the Management of Patients With Peripheral Arterial Disease). J.Am. Coll. Cardiol. 2006; 47:1-192.

[8]	Казанчан П.О., Попов В.А., Дебелый Ю.В. и др. Хирургиче- ская реваскуляризация при критической ишемии. Ангиология и со- судистая хирургия 2000; 3(32): 5.

[9]	Деев Р.В., Григорян А.С., Потапов И.В. и соавт. Мировой опыт и тенденции генной терапии ишемических заболеваний. Ан- гиология и сосудистая хирургия 2011; 17 (2): 145-54.

[10]	Хорев Н.Г., Елыкомов В.А., Залозный Д.А. Терапевтический клеточный ангиогенез в лечении заболеваний периферических ар- терий. Ангиология и сосудистая хирургия 2011; 17(2): 36-44.

[11]

Салафутдинов И.И., Шафигуллина А.К., Ялвач М.Э. и соавт. Эффект одновременной экспрессии различных изоформ фактора роста эндотелия сосудов VEGF и основного фактора роста фибро- бластов FGF2 на пролиферацию эндотелиальных клеток пупочной вены человека HUVEC. Клеточная Трансплантология и Тканевая Ин- женерия 2010; 5(2): 62-7.

[12]	Norrby K., Ridell B. Tumour-type-specific capillary endothelial cell stainability in malignant B-cell lymphomas using antibodies against CD31, CD34 and Factor VIII. APMIS 2003; 111: 483-9.

[13]	Asahara T., Murohara T., Sullivan A. et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997; 275:964-7.

[14]	Швальб П.Г., Гавриленко А.В., Калинин Р.Е. и др. Эффек- тивность и безопасность применения препарата «Неоваскулген» в комплексной терапии пациентов с хронической ишемией нижних ко- нечностей (IIb-III фаза клинических испытаний). Клеточная Транс- плантология и Тканевая Инженерия 2011; 6(3): 76-83.